Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters
How can you be sure a gene therapy is working? What does $11 billion get you in biotech? And who decides which medicines get approved? All that and more on…
How can you be sure a gene therapy is working? What does $11 billion get you in biotech? And who decides which medicines get approved?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. Then we dive into the long history of a gene therapy from Sarepta Therapeutics, a polarizing medicine that promises to change the lives of patients with Duchenne muscular dystrophy. We also break down the rest of the week’s biggest news in biopharma, including some billion-dollar deals and the retirement of perhaps the most storied executive in the business.
What's Your Reaction?
